Topic summary

PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one

Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 30, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.zielinskiTL217 Jul 2026#4

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

Take the reasoning and check the arithmetic; I do not always get it right.

22 likes 11d

OkaforTL3Regular18 Jul 2026#7

il.dumitru, post #6: Taking post #3 at face value and following it one step further. The confident answers on PIONEER 6 cardiovascular safety and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category. Go to post

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

That holds for the case as described. Change the assumptions and it may not.

30 likes in reply to #6 10d

GDashwoodTL3Regular Solution19 Jul 2026#9

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

If it helps: the failure mode here is usually boring rather than dramatic.

8 likes 9d

r.nakamuraTL220 Jul 2026#11

The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.

26 likes 8d

c.delgadoTL225 Jul 2026#26

Offering a way to settle PIONEER 6 cardiovascular safety rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

26 likes 3d

Read the full topic (30 posts)

This topic was referenced in

Food effects on oral incretin absorption: what is documentedCompounds › Oral incretins · 2 replies
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is smallCompounds › Oral incretins · 2 replies

Promoted into the documentation commons. The content of this topic is maintained at Orforglipron — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Something about oral versus injectable exposure does not reconcile…	+19	23	332	8mo
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…	+100	104	4.2k	5mo
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…	+27	31	17k	25d
The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins orforglipron oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Collecting what is known about SOUL trial and oral…		2	7.1k	9h
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…	+11	15	17k	24d

Related topics — sharing the tags PIONEER programme, SOUL trial, randomised trial

Topic	Participants	Replies	Views	Activity
Composite endpoints and the component doing the work Evidence › Trials randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…	+3	7	33k	13h
Journal club: what we got wrong in an earlier session Evidence › Journal club number needed to treat effect size randomised trial journal club On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Bringing a claim rather than a paper, because the claim is the thing circulating. The…	+114	125	2.5k	23h
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Evidence › Journal club randomised trial effect size journal club risk of bias Solved Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Collecting what is known about SURMOUNT-OSA in one place,…	+47	51	617	16mo
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Compounds › Semaglutide STEP programme type 2 diabetes randomised trial effect size Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Putting the numbers in the first…	+125	132	39k	16mo
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…	+11	15	17k	24d